Literature DB >> 18069419

Bone turnover and hip bone mineral density in patients with sarcoidosis.

A Caroline Heijckmann1, Maya S P Huijberts, Jolanda De Vries, Paul P C A Menheere, Eveline Van Der Veer, Arie C Nieuwenhuijzen Kruseman, Bruce H R Wolffenbuttel, Piet Geusens, Marjolein Drent.   

Abstract

BACKGROUND AND AIM OF THE WORK: Sarcoidosis is a chronic inflammatory T-cell-driven disease that can also affect bone. We evaluated bone remodelling and bone mineral density (BMD) in patients with sarcoidosis and their dependency of disease-related and treatment-related factors.
METHODS: In 124 patients BMD of the hip (DXA) and markers of bone resorption (ICTP) and formation (PINP) were evaluated. Furthermore a lateral DXA of the spine for morphometric assessment of vertebral deformities was performed in 87 patients. Potential predictors of bone markers, BMD and determinants of prevalent vertebral deformities were assessed using multiple and logistic regression analysis.
RESULTS: The population studied comprised untreated patients (n=51), patients that previously used glucocorticoids (n=31) and patients currently using glucocorticoids (n=42). In all these groups the age- and gender corrected Z-scores of the hip were normal, except in untreated patients, which revealed an increased Z-score at the trochanter (p = 0.004). In all but the patients currently on glucocorticoids the Z-scores for PINP and ICTP were increased (p < 0.05). In patients currently on glucocorticoids the Z-ICTP was also increased (p < 0.05), but the Z-PINP decreased (p < 0.01 compared to untreated patients). In 20.6% of patients one or more morphometric vertebral deformities were found.
CONCLUSIONS: Hip BMD is normal in patients with sarcoidosis, despite an increased bone turnover. This may imply that in sarcoidosis mechanisms are involved that compensate for the well-known effects of cytokines in inflammatory diseases on osteoclastogenesis and bone resorption. Nonetheless, vertebral deformities suggestive of fracture were found in a significant number of patients which indicates that patients with sarcoidosis still have a relevant fracture risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18069419

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  10 in total

Review 1.  Morbidity and mortality in sarcoidosis.

Authors:  Alicia K Gerke
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

Review 2.  Calcium and vitamin D in sarcoidosis: how to assess and manage.

Authors:  Robert R Burke; Benjamin A Rybicki; D Sudhaker Rao
Journal:  Semin Respir Crit Care Med       Date:  2010-07-27       Impact factor: 3.119

3.  Bone density is normal and does not change over 2 years in sarcoidosis.

Authors:  M J Bolland; M L Wilsher; A Grey; A M Horne; S Fenwick; G D Gamble; I R Reid
Journal:  Osteoporos Int       Date:  2014-08-30       Impact factor: 4.507

4.  Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis.

Authors:  O A Oshagbemi; J H M Driessen; A Pieffers; E F M Wouters; P Geusens; P Vestergaard; J van den Bergh; F M E Franssen; F de Vries
Journal:  Osteoporos Int       Date:  2017-06-21       Impact factor: 4.507

5.  Bone Mineral Loss and Fracture in Sarcoidosis: A Systematic Review and Meta-Analysis.

Authors:  Wai Chung Yong; Sikarin Upala; Anawin Sanguankeo
Journal:  Arch Rheumatol       Date:  2018-09-05       Impact factor: 1.472

6.  Quantitative ultrasound does not identify patients with an inflammatory disease at risk of vertebral deformities.

Authors:  A Caroline Heijckmann; Bianca Dumitrescu; Arie C Nieuwenhuijzen Kruseman; Piet Geusens; Bruce H R Wolffenbuttel; Jolanda De Vries; Marjolein Drent; Maya S P Huijberts
Journal:  BMC Musculoskelet Disord       Date:  2008-05-20       Impact factor: 2.362

7.  Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study.

Authors:  A C Heijckmann; M Drent; B Dumitrescu; J De Vries; A C Nieuwenhuijzen Kruseman; B H R Wolffenbuttel; P Geusens; M S P Huijberts
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

8.  Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients.

Authors:  Nathalie Saidenberg-Kermanac'h; Luca Semerano; Hilario Nunes; Danielle Sadoun; Xavier Guillot; Marouane Boubaya; Nicolas Naggara; Dominique Valeyre; Marie-Christophe Boissier
Journal:  Arthritis Res Ther       Date:  2014-03-24       Impact factor: 5.156

9.  Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort.

Authors:  S Bours; F de Vries; J P W van den Bergh; A Lalmohamed; T P van Staa; H G M Leufkens; P P P Geusens; M Drent; N C Harvey
Journal:  Osteoporos Int       Date:  2015-12-02       Impact factor: 4.507

Review 10.  Sarcoidosis and calcium homeostasis disturbances-Do we know where we stand?

Authors:  Łukasz Gwadera; Adam Jerzy Białas; Mikołaj Aleksander Iwański; Paweł Górski; Wojciech Jerzy Piotrowski
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.